JNJ-56021927
Phase 3 small_molecule active
Quick answer
JNJ-56021927 for High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy. is a Phase 3 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active